99,148 Definium Therapeutics, Inc. $DFTX Shares Sold by Candriam S.C.A.

Key Points

• Candriam S.C.A. reduced its Definium Therapeutics stake by 16.1%, selling 99,148 shares in the third quarter; it retained 515,277 shares, valued at about $19.7 million.
• Analyst sentiment is broadly positive: the stock carries a “Moderate Buy” consensus and a $66 average price target, though one analyst rated it a sell.
• Definium reported a quarterly loss of $1.44 per share, missing the consensus estimate of a $0.55 loss. Company insiders also sold 71,098 shares worth about $2.63 million over the last quarter.

Candriam S.C.A. cut its holdings in Definium Therapeutics, Inc. (NASDAQ:DFTX - Free Report) by 16.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 515,277 shares of the company's stock after selling 99,148 shares during the period. Candriam S.C.A. owned 0.38% of Definium Therapeutics worth $19,683,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC boosted its position in shares of Definium Therapeutics by 28.3% in the third quarter. GAMMA Investing LLC now owns 1,555 shares of the company's stock valued at $59,000 after acquiring an additional 343 shares during the period. Commonwealth Equity Services LLC increased its stake in Definium Therapeutics by 4.0% during the third quarter. Commonwealth Equity Services LLC now owns 9,832 shares of the company's stock valued at $374,000 after acquiring an additional 382 shares during the period. Heritage Wealth Management Inc. CA raised its holdings in Definium Therapeutics by 3.3% in the 3rd quarter. Heritage Wealth Management Inc. CA now owns 12,400 shares of the company's stock valued at $472,000 after acquiring an additional 400 shares in the last quarter. TD Waterhouse Canada Inc. raised its holdings in Definium Therapeutics by 1.2% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 37,147 shares of the company's stock valued at $1,396,000 after acquiring an additional 453 shares in the last quarter. Finally, TFB Advisors LLC lifted its position in shares of Definium Therapeutics by 2.5% in the 3rd quarter. TFB Advisors LLC now owns 22,064 shares of the company's stock worth $840,000 after acquiring an additional 541 shares during the period. 27.91% of the stock is currently owned by institutional investors.

Insider Activity

In other Definium Therapeutics news, insider Matthew T. Wiley sold 3,097 shares of the company's stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $113,257.29. Following the completion of the sale, the insider owned 359,036 shares of the company's stock, valued at approximately $13,129,946.52. This represents a 0.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Brandi Roberts sold 3,377 shares of the stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $123,496.89. Following the completion of the sale, the chief financial officer owned 394,528 shares in the company, valued at approximately $14,427,888.96. This trade represents a 0.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 71,098 shares of company stock worth $2,626,115 over the last quarter. 2.40% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on DFTX shares. Wall Street Zen lowered shares of Definium Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. JPMorgan Chase & Co. began coverage on Definium Therapeutics in a report on Friday, October 9th. They set an "overweight" rating and a $84.00 price objective on the stock. Piper Sandler reiterated an "overweight" rating and issued a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. Bank of America began coverage on shares of Definium Therapeutics in a research report on Tuesday, August 18th. They set a "buy" rating and a $75.00 target price on the stock. Finally, UBS Group reiterated a "buy" rating and set a $70.00 price target on shares of Definium Therapeutics in a research report on Tuesday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $66.00.

Definium Therapeutics Stock Performance

NASDAQ:DFTX opened at $33.27 on Monday. Definium Therapeutics, Inc. has a 1-year low of $10.46 and a 1-year high of $49.70. The business's 50-day moving average price is $36.60 and its two-hundred day moving average price is $29.95. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $4.47 billion, a price-to-earnings ratio of -9.70 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). On average, equities analysts expect that Definium Therapeutics, Inc. will post -3.08 earnings per share for the current year.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.